Alpha 2.0
Login Register
» Authors » Logashvari Naidoo

Logashvari Naidoo

Explore the profile of Logashvari Naidoo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 638
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Biology
Top 10 Co-Authors
Thesla Palanee-Phillips
Nitesha Jeenarain
Jared M Baeten
Elizabeth R Brown
Gonasagrie Nair
Samantha Siva
Krishnaveni Reddy
Nyaradzo Mgodi
Leila E Mansoor
Lydia Soto-Torres
Published In
J Acquir Immune Defic Syndr
AIDS
N Engl J Med
J Int AIDS Soc
Nat Commun
Affiliations
Soon will be listed here.
Recent Articles
1.
Preferences for HIV pre-exposure prophylaxis formulations and delivery among young African women: results of a discrete choice experiment
Dlamini W, Mirembe B, Krows M, Peacock S, Kotze P, Selepe P, et al.
J Int AIDS Soc . 2025 Feb; 28(2):e26422. PMID: 39956930
Introduction: Oral HIV pre-exposure prophylaxis (PrEP) is highly effective, but adherence is challenging for young women. Products centred around women's preferences could address adherence barriers. Using a longitudinal discrete choice...
2.
High recent PrEP adherence with point-of-care urine tenofovir testing and adherence counselling among young African women: results from the INSIGHT cohort
Gati Mirembe B, Donnell D, Krows M, Zwane Z, Bukusi E, Panchia R, et al.
J Int AIDS Soc . 2024 Dec; 27(12):e26389. PMID: 39653676
Introduction: Adolescent girls and young women (AGYW) account for two-thirds of new HIV infections in Africa. African AGYW have had high uptake of oral HIV pre-exposure prophylaxis (PrEP) but low...
3.
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study
Garrett N, Reddy T, Yende-Zuma N, Takalani A, Woeber K, Bodenstein A, et al.
PLOS Glob Public Health . 2024 Dec; 4(12):e0003260. PMID: 39636838
Limited studies have been conducted on the safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income settings, especially those with high-HIV prevalence., The Sisonke Heterologous mRNA-1273 boost after...
4.
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
Bekker L, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, et al.
N Engl J Med . 2024 Jul; 391(13):1179-1192. PMID: 39046157
Background: There are gaps in uptake of, adherence to, and persistence in the use of preexposure prophylaxis for human immunodeficiency virus (HIV) prevention among cisgender women. Methods: We conducted a...
5.
Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial
Goga A, Ramraj T, Naidoo L, Daniels B, Matlou M, Chetty T, et al.
BMC Infect Dis . 2024 Jul; 24(1):712. PMID: 39033300
Background: The ambitious goal to eliminate new pediatric HIV infections by 2030 requires accelerated prevention strategies in high-risk settings such as South Africa. One approach could be pre-exposure prophylaxis (PrEP)...
6.
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial
Kityo C, Mambule I, Musaazi J, Sokhela S, Mugerwa H, Ategeka G, et al.
Lancet Infect Dis . 2024 May; 24(10):1083-1092. PMID: 38821073
Background: Long-acting injectable cabotegravir and rilpivirine is licensed for individualised treatment of HIV-1 infection in resource-rich settings. Additional evidence is required to support use in African treatment programmes where demographic...
7.
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Reeves D, Mayer B, deCamp A, Huang Y, Zhang B, Carpp L, et al.
Nat Commun . 2024 Mar; 15(1):2575. PMID: 38519455
No abstract available.
8.
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Reeves D, Mayer B, deCamp A, Huang Y, Zhang B, Carpp L, et al.
Nat Commun . 2023 Dec; 14(1):8299. PMID: 38097552
The Antibody Mediated Prevention (AMP) trials (NCT02716675 and NCT02568215) demonstrated that passive administration of the broadly neutralizing monoclonal antibody VRC01 could prevent some HIV-1 acquisition events. Here, we use mathematical...
9.
Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex
Browne E, Torjesen K, Gati Mirembe B, Palanee-Phillips T, Jeenarain N, Chitukuta M, et al.
AIDS Care . 2023 Apr; 36(1):80-86. PMID: 37066990
We assessed if acceptability of the dapivirine vaginal ring for HIV prevention differed among the subgroup of women who reported engaging in transactional sex prior to enrollment in MTN-020/ASPIRE (phase...
10.
Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial
Browne E, Brown E, Palanee-Phillips T, Reddy K, Naidoo L, Jeenarain N, et al.
J Acquir Immune Defic Syndr . 2022 Mar; 90(4):418-424. PMID: 35344520
Background: Persistent use of HIV prevention methods can be a challenge, particularly for some younger women. The long-acting, discreet, woman-centric dapivirine vaginal ring offers promise as a prevention method with...